---
title: "BRIEF: Star Sports Medicine doubles in heavily oversubscribed IPO"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/285165672.md"
description: "Star Sports Medicine Co. Ltd.在首次公开募股（IPO）中表现出色，股价在交易开始时上涨三倍，最终在午盘时上涨 132%。该公司以每股 98.50 港元出售了 842 万股，筹集净收益为 7.58 亿港元（9700 万美元）。香港本地投资者的公开发售超额认购超过 7800 倍，国际发售则超额认购 9.4 倍。Star Sports Medicine 是中国第四大运动医学植入物和设备供应商，预计在 2024 年占有约 6.5% 的市场份额。"
datetime: "2026-05-05T07:11:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285165672.md)
  - [en](https://longbridge.com/en/news/285165672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285165672.md)
---

# BRIEF: Star Sports Medicine doubles in heavily oversubscribed IPO

Shares of medical device company **Star Sports Medicine Co. Ltd.** (1609.HK) tripled from their IPO price when trading began on Tuesday, before giving back some of the gains to close up 132% at the midday break.

The company **sold** 8.42 million shares for HK$98.50 each, raising net proceeds of HK$758 million ($97 million). The public offering for local Hong Kong investors was more than 7,800 times oversubscribed, while the international offering was oversubscribed by 9.4 times.

Star Sports Medicine is China’s fourth-largest provider of sports medicine implants and devices, controlling about 6.5% of the market in 2024. The company’s revenue reached 403 million yuan ($59 million) last year, up 23% year-on-year, while its profit jumped 44% to 137 million yuan.

The company plans to use 30% of the IPO proceeds to expand its production capabilities and efficiency. Another 35% will go to R&D, 25% to commercialization, sales, and marketing, and the remaining 10% to general working capital.

_By Lau Chi Hang_

_To subscribe to Bamboo Works weekly free newsletter, click_ _here_

### 相关股票

- [01302.HK](https://longbridge.com/zh-CN/quote/01302.HK.md)
- [159898.CN](https://longbridge.com/zh-CN/quote/159898.CN.md)
- [562600.CN](https://longbridge.com/zh-CN/quote/562600.CN.md)
- [159883.CN](https://longbridge.com/zh-CN/quote/159883.CN.md)

## 相关资讯与研究

- [先健科技拟 18.733 亿元收购北京华医圣杰科技约 96.46% 股权](https://longbridge.com/zh-CN/news/287382267.md)
- [心玮医疗-B 根据特别授权认购新内资股获中国证监会同意注册的批复](https://longbridge.com/zh-CN/news/287205440.md)
- [告别过渡期！乐普医疗正式进入 “85 后二代经营时代”](https://longbridge.com/zh-CN/news/286658586.md)
- [威高股份 5 月 18 日斥资 178.16 万港元回购 52 万股](https://longbridge.com/zh-CN/news/286747038.md)
- [高盛：维持阿里健康 “中性” 评级 降目标价至 4.2 港元](https://longbridge.com/zh-CN/news/286865172.md)